Aptus Pharma Ltd Guidance Report - SOIC x StockScans Report

as of Nov 2026

  1. Preferential issue - ₹44.88 crore raise, utilisation within 36 months Pending - On 17th August 2026, the Board approved raising up to ₹44,88,03,600 via a preferential issue of 16,02,870 shares at ₹280 per share, with proceeds to be utilised within 36 months of receipt - ₹25 crore capex, ₹10 crore working capital, ₹9.88 crore general corporate purposes; the AGM approved it on 14th September 2026. As of 20th October 2026, no share application money was received and no shares were allotted, with the BSE in-principle application under process, so the 36-month window has not commenced.
  2. Consumer Products e-commerce/D2C platform - progressive launch Pending - In the Q1 FY27 PPT, management stated the Consumer Products vertical would generate revenue progressively through a proposed e-commerce/D2C platform, repeated in the Q2 FY27 PPT. As of H1 FY27, Wellness and OTC products contributed \~20% of sales, but no launch of the platform or revenue from it is disclosed in our record.
  3. APTUS Orbit (Franchise Division) - Odisha launch by March 2027 Pending - In the Q4 FY26 PPT, management announced the APTUS Orbit franchise model for penetrating new and underserved markets, especially the north-eastern, Assam and Seven Sisters belt, with Odisha proposed to launch by March 2027. As of H1 FY27 no franchise operations or Odisha launch are disclosed in our record; the March 2027 deadline has not been reached.
  4. APTUS Mindcare (Neuro-Psychiatric Division) - launch in coming years Pending - In the Q4 FY26 PPT, management announced plans to introduce APTUS Mindcare in coming years, focused on neuro and psychiatric therapies, with 50+ products allocated under the 500+ product plan. As of H1 FY27, no launch of the division or neuro-psychiatric product introductions are disclosed in our record.
  5. Product portfolio expansion - from \~250+ to \~500+ products over three years On track - In the Q4 FY26 PPT, management planned to expand the portfolio from \~250+ products to approximately 500+ over the next three years - Pioneer 250+, Wellcare 100+, CD Care 100+, Mindcare 50+. As of H1 FY27 the portfolio comprised more than 300 formulations, up from 250+ at FY26, within the first two quarters of the three-year window.
  6. Own manufacturing - 20% of product portfolio by March 2028 On track - At the Q2 FY27 call, management proposed a manufacturing expansion by March 2028 targeting approximately 20% of the product portfolio through own manufacturing, clarified as making 20% of the current 300 formulations for self-consumption, not CDMO use; the target had been restated from Q4 FY26's nutraceutical/cosmeceutical subsidiary framing to 20% own manufacturing by 2028 from Q1 FY27 onward. As of H1 FY27 the company remains asset-light; a preferential issue is funding ₹25 crore of the initial ₹35 crore capex, a detailed project report has been submitted, and work starts after exchange approval - no facility is under construction in our record.
  7. Global expansion - across Asia, Africa and Latin America by March 2028 Pending - In the Q1 FY27 PPT, management targeted global expansion by March 2028 across named countries in Asia (UAE, Malaysia, Myanmar and others), Africa (Kenya, Uganda, Tanzania and others) and Latin America (Argentina, Brazil, Chile and others), reiterated in the Q2 FY27 PPT and FY26 Annual Report. As of H1 FY27 the company operates a Global vertical, but no export revenue, country registrations or subsidiary incorporation are disclosed as of 30 September 2026; the March 2028 horizon has not been reached.
  8. Pan-India footprint - by March 2029 On track - At the Q2 FY27 call, management stated a long-term objective of a pan-India footprint by 2029, brought forward from the 2030 roadmap referenced in Q4 FY26 materials to March 2029 from Q1 FY27 onward. Before listing the company was present in two states; as of H1 FY27, presence spans Gujarat, Rest of Maharashtra (launched May 2026) and West Bengal (since 2025), with Goa, Rajasthan, Uttar Pradesh and other states proposed for staged launches through March 2029.
  9. 46% geographic coverage across India - by March 2027 On track - At the Q2 FY27 call, management targeted 46% geographic coverage across India by March 2027, reiterated in the Q2 FY27 PPT and the 20th October 2026 announcement. As of 30 September 2026, retail availability exceeded 45,000 outlets with 250+ distributors/sub-distributors; no coverage percentage is disclosed for H1 FY27 and the March 2027 horizon has not been reached.
  10. Bonus issue - 3:2 ratio Delivered - On 24th March 2026, the Board recommended a bonus issue in the ratio of 3:2, capitalising up to ₹10,29,00,000 from the Securities Premium Account, subject to member approval. Members approved via Postal Ballot concluded 25th April 2026, and 1,02,90,000 bonus shares were allotted, raising paid-up capital from ₹6.86 crore to ₹17.15 crore; H1 FY27 EPS was restated for the 3:2 issue of 1.03 crore shares in May 2026.
  11. IPO proceeds utilisation - ₹13.02 crore as per objects Delivered - The DRHP stated IPO net proceeds would be deployed entirely towards the objects in FY 2025-26 - capex ₹173.46 lakh, working capital ₹1,038.00 lakh, and general corporate purposes capped at 15% of gross proceeds or ₹10.00 crore, whichever lower. As on 31.03.2026, the full ₹1,302.00 lakh was utilised as per the objects - capex ₹162.95 lakh, working capital ₹800.00 lakh, general corporate purposes ₹191.05 lakh, IPO expenses ₹148.00 lakh - with NIL deviation, and CARE Ratings confirmed the entire ₹13.02 crore was used exactly as disclosed.